ArticleEuropean radiology2026
Feasibility of lung imaging at 0.55T for assessment of interstitial lung disease in patients with pulmonary sarcoidosis.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the feasibility and diagnostic performance of radiation-free 0.55-T lung MRI for pulmonary sarcoidosis, combining morphological imaging with functional proton MRI ventilation/perfusion metrics, and to explore correlations with pulmonary function testing (PFT). MATERIALS AND
methodsIn this prospective study, 15 patients with pulmonary sarcoidosis and 30 healthy volunteers underwent 0.55-T lung MRI (bSTAR morphology; matrix-pencil based functional proton MRI). CT served as the reference standard for morphological findings (majority vote of experienced readers). Functional maps yielded ventilation defect percentage (VDP), perfusion defect percentage (QDP), and ventilation-perfusion overlap (VQO); thresholds were derived from the healthy cohort. Group comparisons and correlations with PFT were performed.
resultsMRI achieved the highest sensitivity for consolidations (86%) and moderate performance for nodules (67%) as well as ground-glass opacities (70%), but lower sensitivity for reticulations (29%) and traction bronchiectases (27%) compared with CT. Inter-reader and inter-modality agreement were moderate. Functional MP-MRI revealed significantly higher VDP, QDP, and VQO in patients compared with volunteers (all p < 0.01). Strong correlations were found between MRI-derived VDP and RV/TLC ratio (r = 0.90, p < 0.001) and between QDP and FEV1 (r = 0.63, p = 0.01).
conclusionLow-field lung MRI provides complementary information in pulmonary sarcoidosis, enabling structural assessment free of ionizing radiation, with overall moderate agreement compared to CT, and adds valuable regional lung function analysis correlated with PFT. KEY POINTS: Question Can 0.55-T lung MRI supplement CT in pulmonary sarcoidosis by providing structural assessment plus regional ventilation and perfusion metrics linked to pulmonary function? Findings 0.55-T MRI showed high sensitivity for consolidations (86%) and revealed increased ventilation and perfusion defects that correlated strongly with the residual volume-to-total lung capacity ratio. Clinical relevance Low-field lung MRI enables radiation-free assessment of structural and functional lung involvement, offering additional regional information that may support longitudinal monitoring in selected patients with pulmonary sarcoidosis.
Indexed as
Identifiers
42362795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.